Rock & Roll Bash

Holiday
Rock & Roll Bash

Join us on Decemer 3rd for a night of holiday fun – dancing, delicious food and drinks, and an exclusive performance by the world-famous Radio City Rockettes.

The Madison Square Garden Company and AMC Networks host the Holiday Rock & Roll Bash to benefit the Lustgarten Foundation. To date, this fabulous event has raised more than $24 million for pancreatic cancer research.

The Lustgarten Foundation is America’s largest private foundation dedicated to funding pancreatic cancer research. Based in Woodbury, NY, the Foundation supports research to find a cure for pancreatic cancer.

Navigating Pancreatic Cancer

A Guide for Patients & Caregivers

Receive Your Free Copy

Patients and caregivers can also request a free hard copy of this book at contactus@lustgarten.org.  Please write book request in the subject line and provide your name, mailing address, telephone number and email address.

Download a free copy of Navigating Pancreatic Cancer: A Guide for Patients and Caregivers

Download Your Copy Now

Our updated Navigating Pancreatic Cancer: A Guide for Patients & Caregivers handbook is here! Thanks to an educational grant from Celgene and support from Ipsen Pharmaceuticals, this handbook is a valuable resource and roadmap for patients and caregivers faced with a pancreatic cancer diagnosis. Part One addresses immediate needs, including a checklist for newly diagnosed patients; guidance on making treatment decisions; surgery; drug treatments; clinical trials; use of complementary and alternative methods; supportive care; coping; and caring for a loved one.

Part 2 offers background information about the disease and its causes, signs and symptoms, and diagnosis.

We hope this guide will empower patients and caregivers to ask bold questions, seek out cutting-edge treatments, and confront the unique challenges of pancreatic cancer head-on, armed with all of the knowledge needed to make informed decisions.

Bulk orders are available to professionals only. For additional copies to share with colleagues or patients, please fill in our book order form. The books are free, but we do charge $20 per carton of books for shipping and handling. Each carton contains 40 books.

At Lustgarten, we are making progress every day in our fight against pancreatic cancer. Our commitment to everyone impacted by pancreatic cancer has never been stronger, and we will continue to fund research until a cure is found. We believe it’s no longer a matter of “if” we are going to conquer this disease. It’s a matter of when.

Download Your Copy Now

Related Topics

View our blog series.
Learn how you can get involved.
Find an event in your community.

 

Yale scientists help immune system find hidden cancer cells

Cancer cells are masters at avoiding detection, but a new system developed by Yale scientists can make them stand out from the crowd and help the immune system spot and eliminate tumors that other forms of immunotherapies might miss, the researchers report Oct. 14 in the journal Nature Immunology. The new system reduced or eliminated melanoma and triple-negative breast and pancreatic tumors in mice, even those located far from the primary tumor source, the researchers report.

Rafael Pharmaceuticals Reaches Milestone of 100 Patients Enrolled in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) for Patients with Metastatic Pancreatic Cancer

 Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that it has enrolled 100 patients in its pivotal Phase 3 clinical trial for metastatic pancreatic cancer (AVENGER 500). The multicenter, open-label, randomized trial is evaluating the efficacy and safety of Rafael’s lead compound CPI-613®️ (devimistat) in combination with modified FOLFIRINOX (mFFX) as first-line therapy in patients with metastatic adenocarcinoma of the pancreas. The global study is active and still open for patient enrollment in sites across the United States, France, Israel and South Korea. “Enrolling 100 patients in our pancreatic cancer clinical trial is an important milestone for Rafael,” said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals.

Study: Innovative pancreatic cancer treatment may rev up immune system

A University of Rochester Wilmot Cancer Institute research team reports that combining a type of radiation therapy with immunotherapy not only cures pancreatic cancer in mice, but appears to reprogram the immune system to create an “immune memory” in the same way that a vaccine keeps the flu away. The result is that the combination treatment also destroyed pancreatic cells that had spread to the liver, a common site for metastatic disease. The journal Cell Reports published the study, with Scott Gerber, Ph.D., as corresponding author, and Bradley Mills, Ph.D., a post-doctoral fellow in the Gerber Lab, as first author.

2019 Long Island Pancreatic Cancer Research Walk

Nearly $1 Million Raised for Research!

Thank You, Long Island!

Our Long Island Walk was a huge success, and we are incredibly grateful to our presenting sponsor, Northwell Health, and all of the walkers, team members, researchers, volunteers, speakers and other sponsors who shared this day of hope with us. Because of your support, we had one of our largest crowds to date, welcoming 7,000 participants, including many walkers who have been with us since our first walk in 2001 and family members who have lost loved ones to this disease but who are more committed than ever to joining us on our journey toward a cure.

2019 Long Island Walk Charles F. DolanWe are honored that our founder, Charles Dolan, addressed the crowd with his heartfelt speech about how proud Marc Lustgarten would be to witness the breakthroughs made in treating and detecting this disease. The most inspiring part of the walk was seeing the more than 20 survivors who participated in our ribbon-cutting ceremony. They shared their stories, celebrated with their families, and served as a powerful example of how much progress we are making through research.

Thanks to your generosity, we are well on our way toward our $1 million goal. We encourage you to continue fundraising, as your page will stay open through the rest of the year. We look forward to seeing you at the Long Island Walk’s 20th anniversary next fall!

View all walk photos.

 

Related Topics:

Watch News12’s report on the walk.
Read Newsday’s article about the walk.

 

Cancer Is Still Beating Us—We Need a New Start

I have been studying and treating cancer for 35 years, and here’s what I know about the progress made in that time: There has been far less than it appears. Despite some advances, the treatments for most kinds of cancer continue to be too painful, too damaging, too expensive and too ineffective. The same three methods—surgery, chemotherapy and radiotherapy—have prevailed for a half-century.

Consider acute myeloid leukemia, the bone-marrow malignancy that is my specialty. AML accounts for a third of all leukemia cases. Currently, the average age of diagnosis is 68; roughly 11,000 individuals die annually from the disease

Response rate to albumin-bound paclitaxel plus gemcitabine plus cisplatin treatment among patients with advanced pancreatic cancer: A phase 1b/2 pilot clinical tria

 Adding a drug that targets a molecular vulnerability in pancreatic cancer could provide substantial benefit to patients, according to a clinical trial study by the HonorHealth Research Institute and the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, in conjunction with the Pancreatic Cancer Research Team and Cancer Research And Biostatistics. Published today in the Journal of the American Medical Association (JAMA) Oncology, researchers found that among a clinical trial of 25 patients, adding the drug cisplatin to a current standard-of-care drug regimen resulted in substantial tumor shrinkage for 71 percent of those patients, and dramatically increased survival beyond one year.

Drug Trio Improves Odds Against Advanced Pancreatic Cancer

A three-drug chemo cocktail appears to shrink tumors and improve survivorship among pancreatic cancer patients, a new, small study shows. Tumors substantially shrank for just over 71% of patients treated with a three-drug regimen of nab-paclitaxel, gemcitabine and platinum-based cisplatin, the researchers found. Further, 16 patients (64%) out of the 25 treated were still alive a year after treatment, more than double the average 26% one-year survival rate for people with advanced pancreatic cancer.

Fungal Invasion of Pancreas Creates Cancer Risk

Certain fungi move from the gut to the pancreas, expand their population more than a thousand-fold, and encourage pancreatic cancer growth, a new study finds. Published online in Nature October 2, the study is the first to offer strong evidence that the mycobiome—the local mix of fungal species in the pancreas—can trigger changes that turn normal cells into pancreatic ductal adenocarcinoma (PDA). This form of cancer is usually fatal within two years.

Get Involved Today

Get inspired and connect with patients, survivors and loved ones who are all on the same journey.

Back to Top